NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AbolerIS Pharma

AbolerIS Pharma

Private
BelgiumHealthcare & Life Scienceshttps://aboleris-pharma.com/

Last Round

Series A

Sep 18, 2023

Total Funding Raised

$32.1M

Company Overview

AbolerIS Pharma is a biotechnology company that develops novel immunomodulatory antibodies to induce immune tolerance for treating inflammatory, autoimmune, and degenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyimmunomodulatory therapymonoclonal antibodyautoimmune diseaseorgan transplant rejectionimmune tolerancebiopharmadrug discoveryclinical-stage biotechcytokine therapyanti-CD45RCclinical trialstherapeutic pipelinebiotech startupdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AbolerIS Pharma Comparables

Compare AbolerIS Pharma with similar companies based on industry and business-model similarity.

AbolerIS Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Revolo Biotherapeutics
76%
NXI Therapeutics
75%
UCB
74%

AbolerIS Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 18, 2023
SeedNov 4, 2020

Key People

Founding team and executive leadership

Tomas Van Dyck

Chief Financial Officer

Executive Team

AbolerIS Pharma Investors

Notable investors and investment history

AbolerIS Pharma investors
InvestorRounds
Federal Holding and Investment CompanySeries A
Newton BiocapitalSeed, Series A
Wallonie EntreprendreSeries A
Criteria Capital RiscSeries A
SambrinvestSeries A
Sound BioventuresSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 30, 2025

    Philippe Alen appointed as the new Chief Business Officer.

  • Sep 18, 2023

    $29.1M round led by Caixa Capital Risc

AbolerIS Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AbolerIS Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AbolerIS Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelgium
Employee Range14
Year Founded2019
Last FundingSep 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.